Prevents deep vein thrombosis (DVT). ANDA 206812, held by Hengrui Pharma. Fondaparinux Sodium.
As of Nov 16, 2026, ANDA 206812 (Fondaparinux Sodium), held by Hengrui Pharma, was first approved by FDA on May 15, 2018, with 0 approved supplements and 0 published complete response letters.
Fondaparinux sodium injection is a Factor Xa inhibitor (anticoagulant) indicated for: Prophylaxis of deep vein thrombosis (DVT) in adult patients undergoing hip fracture surgery (including extended prophylaxis), hip replacement surgery, knee replacement surgery, or abdominal surgery. Treatment of DVT or acute pulmonary embolism (PE) in adult patients when administered in conjunction with warfarin. ( 1.2, 1.3 ) Treatment of venous thromboembolism (VTE) in pediatric patients aged 1 year or older weighing at least 10 kg. 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 15, 2018 | Original application | Approved | None posted |
| Fondaparinux Sodium2.5MG/0.5ML (2.5MG/0.5ML) · solution;subcutaneous | Fondaparinux Sodium | Discontinued |
| Fondaparinux Sodium5MG/0.4ML (5MG/0.4ML) · solution;subcutaneous | Fondaparinux Sodium | Discontinued |
| Fondaparinux Sodium7.5MG/0.6ML (7.5MG/0.6ML) · solution;subcutaneous | Fondaparinux Sodium | Discontinued |
| Fondaparinux Sodium10MG/0.8ML (10MG/0.8ML) · solution;subcutaneous | Fondaparinux Sodium | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters